|
業務類別
|
Biotechnology |
|
業務概覽
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International. |
| 公司地址
| 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116 |
| 電話號碼
| +1 857 264-4280 |
| 傳真號碼
| +1 857 264-4299 |
| 公司網頁
| https://www.rhythmtx.com |
| 員工數量
| 414 |
| Mr. Christopher P. German |
Corporate Controller and Principal Accounting Officer |
-- |
26/02/2026 |
| Mr. Joseph Shulman |
Chief Technical Officer |
美元 449.05K |
29/04/2025 |
| Ms. Pamela J. Cramer |
Chief Human Resources Officer |
-- |
29/04/2025 |
| Ms. Jennifer Lee |
Executive Vice President and Head of North America |
美元 488.27K |
29/04/2025 |
| Mr. Yann Mazabraud |
Executive Vice President and Head of International |
美元 467.22K |
29/04/2025 |
| Mr. Hunter C. Smith |
Chief Financial Officer and Treasurer |
美元 499.39K |
26/02/2026 |
| Mr. Alastair Garfield |
Chief Scientific Officer |
-- |
29/04/2025 |
| Dr. David P. Meeker,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 740.47K |
26/02/2026 |
|
|
| Mr. Stuart A. Arbuckle |
Independent Director |
26/02/2026 |
| Ms. Lynn A. Tetrault, J.D. |
Independent Director |
26/02/2026 |
| Ms. Jennifer L. Good |
Independent Director |
26/02/2026 |
| Mr. David W.J. McGirr, M.B.A. |
Independent Director |
26/02/2026 |
| Mr. Christophe R. Jean |
Independent Director |
26/02/2026 |
| Ms. Kimberly J. Popovits |
Director |
03/04/2026 |
| Dr. David P. Meeker,M.D. |
Chairman of the Board, President and Chief Executive Officer |
26/02/2026 |
|
|
|
|
